CORDIS
EU research results

CORDIS

English EN
PET Imaging of Alpha-Synuclein Fibril Formation

PET Imaging of Alpha-Synuclein Fibril Formation

Objective

Too often, physicians have to rely on a trial and error strategy until the most effective treatment for an individual patient is identified. This leads to a critical loss of time, making the healthcare system ineffective and expensive. In respect to drug development, a high failure rate is apparent at all stages of development and ways to reduce this have high priority for the pharmaceutical industry. To this end, drug development and medicinal treatment need to be more personalized and molecular imaging techniques, in particular Positron Emission Tomography (PET) imaging, can be used to achieve this by 1) evaluating the effectiveness of new treatments emerging from the pharmaceutical industry, 2) improving the ability to diagnose diseases, and 3) aid tailoring the treatment based on individual patient pathology. A limiting factor to develop new effective PET imaging probes is the insufficient number of radiopharmaceutical scientists presently available. Our consortium has assembled 6 radiopharmaceutical frontline academic and 10 non-academic partners to address this problem and train the next generation of radiopharmaceutical scientists. Our training will be focused on an unmet scientific need for Parkinson’s Disease (PD). Fibril formation of protein α-synuclein is thought to be the hallmark for PD, but presently, there are no validated PET tracers available for visualization of pathogenic aggregates of this protein. Our scientific goal is to develop such tracer. A successful tracer will have a strong impact on PD-diagnosis and facilitate the development of effective disease modifying treatments. To reach our goals, it is necessary to train our early stage researchers in a highly interdisciplinary fashion spanning from chemistry, over biology, GMP and pharmacy to nuclear medicine. Furthermore, this consortium will train entrepreneurial skills and facilitate start up new enterprises in the current favorable radioisotope market situation.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KOBENHAVNS UNIVERSITET

Address

Norregade 10
1165 Kobenhavn

Denmark

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 892 566

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 297 522

STICHTING VUMC

Netherlands

EU Contribution

€ 796 859,64

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 563 965,92

JOHANNES GUTENBERG-UNIVERSITAT MAINZ

Germany

EU Contribution

€ 252 788,40

ELYSIA

Belgium

EU Contribution

€ 256 320

BIOARCTIC AB

Sweden

EU Contribution

€ 281 982,96

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 758 365,20

Partners (8)

Sort alphabetically

Expand all

ION BEAM APPLICATIONS SA

PMOD TECHNOLOGIES GMBH

Eckert & Ziegler Eurotope GmbH

H. LUNDBECK AS

NOVO NORDISK A/S

POSITRONPHARMA SA

TAGWORKS PHARMACEUTICALS BV

UNIVERSITE DE LIEGE

Project information

Grant agreement ID: 813528

Status

Ongoing project

  • Start date

    1 September 2018

  • End date

    31 August 2022

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 4 100 370,12

  • EU contribution

    € 4 100 370,12

Coordinated by:

KOBENHAVNS UNIVERSITET

Denmark